Sanofi SA at Bank of America Merrill Lynch Global Healthcare Conference Transcript
To kick off. So welcome to the next session. I'm very pleased to be able to have from Sanofi with us today. Two different areas to talk about. So we'll probably try and split the timing roughly equally between the two. So we have Naimish Patel, who's the Therapeutic Area Head, for Immunology and Inflammation. And then François Sandre, who is the Head of Vaccines in Europe, so probably two the core pieces of Sanofi that we can get to discuss here. So welcome. Thanks for the time today.
Questions & Answers
And I might kick off on the Immunology side with you, Naimish. So obviously, one of the biggest and best drivers of Sanofi at the moment is Dupixent across multiple different indications. So quite a tough act to follow if you're looking at developments. But perhaps you can just run through where you see where, particularly in atopic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
